{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:24:29Z","timestamp":1775031869328,"version":"3.50.1"},"reference-count":107,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Arterial and venous thromboses differ in pathophysiology but share overlapping risk factors such as obesity, metabolic syndrome, and aging. Patients with established arterial disease, such as coronary artery disease, stroke, and peripheral artery disease, may develop venous thromboembolism (VTE) during the acute or chronic phase of their illness. This creates therapeutic tension when anticoagulation for VTE overlaps with antiplatelet therapy. We propose a stepwise clinical approach that first identifies precipitating factors for VTE, then modifies antiplatelet therapy according to the chronicity of the arterial condition and finally estimates thrombosis against bleeding risk aided by scoring systems, available evidence for combination treatment, and interdisciplinary collaboration. Two clinical cases exemplify this stepwise approach.<\/jats:p>","DOI":"10.1182\/hematology.2025000683","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:05Z","timestamp":1764943685000},"page":"22-33","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Managing patients with a history of arterial disease and new venous thromboembolism"],"prefix":"10.1182","volume":"2025","author":[{"given":"Echo","family":"Deng","sequence":"first","affiliation":[{"name":"1 Haematology Department, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freda H.","family":"Passam","sequence":"additional","affiliation":[{"name":"1 Haematology Department, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia"},{"name":"2 Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"5","key":"2025120616324920900_hem2025000683C1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/ATVBAHA.124.320151","article-title":"Global health burden of venous thromboembolism","volume":"44","author":"Wendelboe","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2025120616324920900_hem2025000683C2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/cells14020144","article-title":"The link between venous and arterial thrombosis: is there a role for endothelial dysfunction?","volume":"14","author":"Donadini","year":"2025","journal-title":"Cells"},{"issue":"23","key":"2025120616324920900_hem2025000683C3","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood.2023021638","article-title":"How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?","volume":"143","author":"May","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025120616324920900_hem2025000683C4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.13329","article-title":"Impact of incident myocardial infarction on the risk of venous thromboembolism: the Troms\u00f8 Study","volume":"14","author":"Rinde","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025120616324920900_hem2025000683C5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5853\/jos.2022.02215","article-title":"Trends in venous thromboembolism readmission rates after ischemic stroke and intracerebral hemorrhage","volume":"25","author":"Shu","year":"2023","journal-title":"J Stroke"},{"issue":"4","key":"2025120616324920900_hem2025000683C6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1538-7836.2009.03279.x","article-title":"Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study","volume":"7","author":"S\u00f8rensen","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2025120616324920900_hem2025000683C7","doi-asserted-by":"crossref","first-page":"1005557","DOI":"10.1016\/j.jacadv.2023.100555","article-title":"Venous thromboembolism in patients with atrial fibrillation: a systematic review and meta-analysis of 4,170,027 patients","volume":"2","author":"Pastori","year":"2023","journal-title":"JACC Adv"},{"issue":"1","key":"2025120616324920900_hem2025000683C8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11739-024-03765-7","article-title":"Venous thrombosis and obesity: from clinical needs to therapeutic challenges","volume":"20","author":"La Rosa","year":"2025","journal-title":"Intern Emerg Med"},{"issue":"1","key":"2025120616324920900_hem2025000683C9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/bloodadvances.2019000561","article-title":"Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis","volume":"4","author":"Stewart","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2025120616324920900_hem2025000683C10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025120616324920900_hem2025000683C11","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"1","key":"2025120616324920900_hem2025000683C12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1467-842X.2006.tb00077.x","article-title":"Air travel and the risk of deep vein thrombosis","volume":"30","author":"Becker","year":"2006","journal-title":"Aust N Z J Public Health"},{"issue":"19","key":"2025120616324920900_hem2025000683C13","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025120616324920900_hem2025000683C14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/bmb\/ldx018","article-title":"Anticoagulation after coronary stenting: a systemic review","volume":"123","author":"Dong","year":"2017","journal-title":"Br Med Bull"},{"issue":"1","key":"2025120616324920900_hem2025000683C15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4244\/EIJV9I1A10","article-title":"Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting","volume":"9","author":"Iqbal","year":"2013","journal-title":"EuroIntervention"},{"issue":"7138","key":"2025120616324920900_hem2025000683C16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"issue":"3","key":"2025120616324920900_hem2025000683C17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annemergmed.2004.10.001","article-title":"The mortality of untreated pulmonary embolism in emergency department patients","volume":"45","author":"Calder","year":"2005","journal-title":"Ann Emerg Med"},{"issue":"23, suppl 1","key":"2025120616324920900_hem2025000683C18","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"2025120616324920900_hem2025000683C19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2025120616324920900_hem2025000683C20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions","volume":"21","author":"Lip","year":"2018","journal-title":"EP Europace"},{"issue":"6","key":"2025120616324920900_hem2025000683C21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"2025120616324920900_hem2025000683C22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"12","key":"2025120616324920900_hem2025000683C23","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"10498","key":"2025120616324920900_hem2025000683C24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(25)00439-8","article-title":"Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)","volume":"406","author":"Dehbi","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"2025120616324920900_hem2025000683C25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio- Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"2025120616324920900_hem2025000683C26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/aje\/kwaa051","article-title":"Burden of peripheral artery disease on mortality and incident cardiovascular events","volume":"189","author":"Unkart","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2025120616324920900_hem2025000683C27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's choice\u2014European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"21","key":"2025120616324920900_hem2025000683C28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2025120616324920900_hem2025000683C29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2018.08.007","article-title":"Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis","volume":"206","author":"Lee","year":"2018","journal-title":"Am Heart J"},{"issue":"12","key":"2025120616324920900_hem2025000683C30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616324920900_hem2025000683C31","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1038\/s41598-025-02171-z","article-title":"Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis","volume":"15","author":"Carron","year":"2025","journal-title":"Sci Rep"},{"issue":"13","key":"2025120616324920900_hem2025000683C32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"2025120616324920900_hem2025000683C33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"21","key":"2025120616324920900_hem2025000683C34","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"2025120616324920900_hem2025000683C35","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2025120616324920900_hem2025000683C36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/STROKEAHA.108.521419","article-title":"The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry","volume":"40","author":"Weimar","year":"2009","journal-title":"Stroke"},{"issue":"14","key":"2025120616324920900_hem2025000683C37","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"2025120616324920900_hem2025000683C38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score","volume":"8","author":"Barbar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2025120616324920900_hem2025000683C39","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"2025120616324920900_hem2025000683C40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejvs.2021.12.019","article-title":"The OAC3-PAD risk score predicts major bleeding events one year after hospitalisation for peripheral artery disease","volume":"63","author":"Behrendt","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"14","key":"2025120616324920900_hem2025000683C41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"de Winter","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"2025120616324920900_hem2025000683C42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/eurheartj\/ehad618","article-title":"The Vienna Prediction Model for identifying patients at low risk of recurrent venous thromboembolism: a prospective cohort study","volume":"45","author":"Kyrle","year":"2024","journal-title":"Eur Heart J"},{"issue":"3","key":"2025120616324920900_hem2025000683C43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/rth2.12214","article-title":"Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism","volume":"3","author":"Klok","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2025120616324920900_hem2025000683C44","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism","volume":"117","author":"Klok","year":"2017","journal-title":"Thromb Haemost"},{"issue":"5","key":"2025120616324920900_hem2025000683C45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2025120616324920900_hem2025000683C46","unstructured":"National Institute for Health and Care Excellence (NICE). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. (NICE guideline NG158). Updated 2023. Accessed 10Jan.2025. nice.org.uk\/guidance\/ng158"},{"issue":"15","key":"2025120616324920900_hem2025000683C47","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1182\/bloodadvances.2022007027","article-title":"Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism","volume":"6","author":"Wells","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025120616324920900_hem2025000683C48","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.rpth.2024.102569","article-title":"Impact of the VTE-PREDICT calculator on clinicians' decision making in fictional patients with venous thromboembolism: a randomized controlled trial","volume":"8","author":"Duijzer","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"2025120616324920900_hem2025000683C49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.thromres.2021.11.001","article-title":"Management of acute venous thromboembolism in patients taking antiplatelet therapy","volume":"208","author":"Giraud","year":"2021","journal-title":"Thromb Res"},{"issue":"19","key":"2025120616324920900_hem2025000683C50","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"2025120616324920900_hem2025000683C51","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.jhepr.2024.101116","article-title":"Direct oral anticoagulants in cirrhosis: Rationale and current evidence","volume":"6","author":"Pereira Portela","year":"2024","journal-title":"JHEP Rep"},{"issue":"9(suppl 2)","key":"2025120616324920900_hem2025000683C52","first-page":"102931","article-title":"Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism. Late breaking abstract ISTH 2025","volume":"2025","author":"Castellucci","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2025120616324920900_hem2025000683C53","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jth.14807","article-title":"Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: systematic review and meta-analysis","volume":"18","author":"Valeriani","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025120616324920900_hem2025000683C54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.11.014","article-title":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","volume":"85","author":"Abrignani","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"19","key":"2025120616324920900_hem2025000683C55","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","article-title":"Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"issue":"10480","key":"2025120616324920900_hem2025000683C56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"issue":"25","key":"2025120616324920900_hem2025000683C57","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.122.059405","article-title":"Rivaroxaban 2.5\u200amg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis","volume":"145","author":"Pogosova","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"2025120616324920900_hem2025000683C58","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.amjcard.2017.12.014","article-title":"Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"121","author":"Cavallari","year":"2018","journal-title":"Am J Cardiol"},{"issue":"11","key":"2025120616324920900_hem2025000683C59","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.amjmed.2017.03.057","article-title":"Safety and efficacy of dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention","volume":"130","author":"Agarwal","year":"2017","journal-title":"Am J Med"},{"issue":"5","key":"2025120616324920900_hem2025000683C60","doi-asserted-by":"crossref","first-page":"102984","DOI":"10.1016\/j.rpth.2025.102984","article-title":"Artificial intelligence in clinical thrombosis and hemostasis: a review","volume":"9","author":"Kuan","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025120616324920900_hem2025000683C61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jvsv.2022.08.009","article-title":"Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention","volume":"11","author":"Kindell","year":"2023","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"6","key":"2025120616324920900_hem2025000683C62","doi-asserted-by":"crossref","first-page":"e2215580","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2025120616324920900_hem2025000683C63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1358863X19833451","article-title":"Rate and impact of venous thromboembolism in patients with ST-segment elevation myocardial infarction","volume":"24","author":"Al-Ogaili","year":"2019","journal-title":"Vasc Med"},{"issue":"8","key":"2025120616324920900_hem2025000683C64","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/jth.14865","article-title":"Comorbidity and risk of venous thromboembolism after hospitalization for first-time myocardial infarction","volume":"18","author":"W\u00fcrtz","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2025120616324920900_hem2025000683C65","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.111.025627","article-title":"Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis","volume":"124","author":"S\u00f8rensen","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"2025120616324920900_hem2025000683C66","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.117.031062","article-title":"Combined antiplatelet therapy and venous thromboembolism in symptomatic atherosclerosis","volume":"137","author":"Cavallari","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"2025120616324920900_hem2025000683C67","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"2025120616324920900_hem2025000683C68","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/01.STR.0000140741.13279.4f","article-title":"Venous thromboembolism after acute ischemic stroke","volume":"35","author":"Kelly","year":"2004","journal-title":"Stroke"},{"issue":"3","key":"2025120616324920900_hem2025000683C69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.thromres.2006.03.010","article-title":"Pharmacological prophylaxis for deep-vein thrombosis and pulmonary embolism in acute ischemic stroke","volume":"119","author":"Kamphuisen","year":"2007","journal-title":"Thromb Res"},{"issue":"11","key":"2025120616324920900_hem2025000683C70","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/j.1538-7836.2011.04486.x","article-title":"Progression and regression of deep vein thrombosis in immobile stroke patients","volume":"9","author":"Dennis","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2025120616324920900_hem2025000683C71","doi-asserted-by":"crossref","first-page":"e000372","DOI":"10.1161\/JAHA.113.000372","article-title":"Pulmonary embolism in ischemic stroke","volume":"2","author":"Pongmoragot","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2025120616324920900_hem2025000683C72","doi-asserted-by":"crossref","first-page":"e004311","DOI":"10.1161\/JAHA.116.004311","article-title":"Ischemic stroke and venous thromboembolism: the Troms\u00f8 Study","volume":"5","author":"Rinde","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2025120616324920900_hem2025000683C73","doi-asserted-by":"crossref","first-page":"e000467","DOI":"10.1161\/JAHA.113.000467","article-title":"D-dimer levels over time and recurrent venous thromboembolism: Vienna prediction model update","volume":"3","author":"Eichinger","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2025120616324920900_hem2025000683C74","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2 rule in women with unprovoked venous thrombosis","volume":"356","author":"Rodger","year":"2017","journal-title":"BMJ"},{"issue":"21","key":"2025120616324920900_hem2025000683C75","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2016.03.485","article-title":"DAPT score utility for risk prediction","volume":"67","author":"Kereiakes","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10073","key":"2025120616324920900_hem2025000683C76","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"PRECISE-DAPT score derivation and validation","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"2025120616324920900_hem2025000683C77","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","article-title":"SMART risk score development and validation","volume":"99","author":"Dorresteijn","year":"2013","journal-title":"Heart"},{"issue":"19","key":"2025120616324920900_hem2025000683C78","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of 10-year recurrent vascular risk","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"issue":"28","key":"2025120616324920900_hem2025000683C79","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","article-title":"SCORE2-Diabetes cardiovascular risk estimation","volume":"44","author":"SCORE2-Diabetes Working Group","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"2025120616324920900_hem2025000683C80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refined stroke and thromboembolism risk stratification in atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"3","key":"2025120616324920900_hem2025000683C81","doi-asserted-by":"crossref","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","article-title":"ATRIA stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"2025120616324920900_hem2025000683C82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Predicting hemorrhage in atrial fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"46","key":"2025120616324920900_hem2025000683C83","first-page":"3258","article-title":"ORBIT bleeding score","volume":"36","author":"O\u2019Brien","year":"2015"},{"issue":"8","key":"2025120616324920900_hem2025000683C84","doi-asserted-by":"crossref","first-page":"e0160046","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"issue":"16","key":"2025120616324920900_hem2025000683C85","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone (CHARISMA)","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616324920900_hem2025000683C86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Aspirin for primary prevention: cardiovascular and bleeding outcomes","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"2025120616324920900_hem2025000683C87","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.109.919001","article-title":"Bleeding risk after DES implantation on clopidogrel","volume":"3","author":"Tsai","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2025120616324920900_hem2025000683C88","doi-asserted-by":"crossref","first-page":"e082561","DOI":"10.1136\/bmj-2024-082561","article-title":"P2Y12 inhibitor vs aspirin after PCI: IPD meta-analysis","volume":"389","author":"Giacoppo","year":"2025","journal-title":"BMJ"},{"issue":"8","key":"2025120616324920900_hem2025000683C89","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCULATIONAHA.123.067283","article-title":"Ticagrelor monotherapy after ACS PCI: IPD meta-analysis","volume":"149","author":"Baber","year":"2024","journal-title":"Circulation"},{"issue":"16","key":"2025120616324920900_hem2025000683C90","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy in AF","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"2025120616324920900_hem2025000683C91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2022.04.004","article-title":"Ticagrelor vs clopidogrel in high bleeding risk ACS","volume":"216","author":"Wang","year":"2022","journal-title":"Thromb Res"},{"issue":"9","key":"2025120616324920900_hem2025000683C92","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Apixaban for acute venous thromboembolism (AMPLIFY)","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2025120616324920900_hem2025000683C93","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban vs warfarin in AF (ARISTOTLE)","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616324920900_hem2025000683C94","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"2025120616324920900_hem2025000683C95","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Rivaroxaban for symptomatic VTE","volume":"363","author":"EINSTEIN","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616324920900_hem2025000683C96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban vs warfarin in AF (ROCKET AF)","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"2025120616324920900_hem2025000683C97","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended VTE treatment (EINSTEIN CHOICE)","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2025120616324920900_hem2025000683C98","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran vs warfarin in AF (RE-LY)","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"2025120616324920900_hem2025000683C99","first-page":"1406","article-title":"Edoxaban vs warfarin in VTE","volume":"369","author":"Hokusai-VTE","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2025120616324920900_hem2025000683C100","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for AF and stable CAD: meta-analysis","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2025120616324920900_hem2025000683C101","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease (COMPASS)","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"key":"2025120616324920900_hem2025000683C102","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"WOEST trial: clopidogrel with or without aspirin in patients on oral anticoagulation undergoing PCI","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"18","key":"2025120616324920900_hem2025000683C103","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","article-title":"Triple antithrombotic therapy in AF and coronary stents","volume":"121","author":"Paikin","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"2025120616324920900_hem2025000683C104","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2025120616324920900_hem2025000683C105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in non- surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025120616324920900_hem2025000683C106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"TIMI Phase I trial","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"issue":"23","key":"2025120616324920900_hem2025000683C107","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"BARC bleeding definitions consensus","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/22\/2469960\/22deng.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/22\/2469960\/22deng.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:04Z","timestamp":1765056784000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/22\/556883\/Managing-patients-with-a-history-of-arterial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000683","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}